These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma. Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516 [TBL] [Abstract][Full Text] [Related]
26. Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma. Colebatch AJ; Paver EC; Vergara IA; Thompson JF; Long GV; Wilmott JS; Scolyer RA Pathology; 2022 Aug; 54(5):533-540. PubMed ID: 35248370 [TBL] [Abstract][Full Text] [Related]
27. The role of BRAF mutations in primary melanoma growth rate and survival. Mar VJ; Liu W; Devitt B; Wong SQ; Dobrovic A; McArthur GA; Wolfe R; Kelly JW Br J Dermatol; 2015 Jul; 173(1):76-82. PubMed ID: 25752325 [TBL] [Abstract][Full Text] [Related]
28. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Tetzlaff MT; Pattanaprichakul P; Wargo J; Fox PS; Patel KP; Estrella JS; Broaddus RR; Williams MD; Davies MA; Routbort MJ; Lazar AJ; Woodman SE; Hwu WJ; Gershenwald JE; Prieto VG; Torres-Cabala CA; Curry JL Hum Pathol; 2015 Aug; 46(8):1101-10. PubMed ID: 26058727 [TBL] [Abstract][Full Text] [Related]
29. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017 [TBL] [Abstract][Full Text] [Related]
30. Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo. Tschandl P; Berghoff AS; Preusser M; Pammer J; Pehamberger H; Kittler H Br J Dermatol; 2016 Feb; 174(2):364-70. PubMed ID: 26613644 [TBL] [Abstract][Full Text] [Related]
31. Clinicopathological Characteristics of BRAF V600E Mutated Melanomas in the Dalmatian Region of Croatia. Bezić J; Kuret S; Vrbičić B; Smolić J; Borić I; Škifić I; Ledina D; Božić J Acta Dermatovenerol Croat; 2019 Dec; 27(4):225-230. PubMed ID: 31969234 [TBL] [Abstract][Full Text] [Related]
37. The \textit{BRAF} V600E mutation in single- institution study of Russian melanoma patients. Lyubchenko L; Emelyanova M; Shamanin V; Demidov L; Zasedatelev A; Nasedkina T Cancer Biomark; 2016; 16(1):153-60. PubMed ID: 26600396 [TBL] [Abstract][Full Text] [Related]
38. Association between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma. Wu S; Kuo H; Li WQ; Canales AL; Han J; Qureshi AA Cancer Causes Control; 2014 Oct; 25(10):1379-86. PubMed ID: 25048604 [TBL] [Abstract][Full Text] [Related]
39. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. Colomba E; Hélias-Rodzewicz Z; Von Deimling A; Marin C; Terrones N; Pechaud D; Surel S; Côté JF; Peschaud F; Capper D; Blons H; Zimmermann U; Clerici T; Saiag P; Emile JF J Mol Diagn; 2013 Jan; 15(1):94-100. PubMed ID: 23159108 [TBL] [Abstract][Full Text] [Related]
40. Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma. Melchior L; Grauslund M; Bellosillo B; Montagut C; Torres E; Moragón E; Micalessi I; Frans J; Noten V; Bourgain C; Vriesema R; van der Geize R; Cokelaere K; Vercooren N; Crul K; Rüdiger T; Buchmüller D; Reijans M; Jans C Exp Mol Pathol; 2015 Dec; 99(3):485-91. PubMed ID: 26407762 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]